Odyssey Therapeutics, Inc.

ODTX chart

Odyssey Therapeutics, Inc. news

• Several Insiders Invested In Odyssey Therapeutics Flagging Positive News

  Simply Wall St · Nov 11, 6:00 AM EST

• FMR LLC Adds 1,059,975 Shares of Odyssey Therapeutics (ODTX) in Q3 2026 Filing

  GuruFocus · Nov 10, 10:33 PM EST

• Odyssey Therapeutics publishes TNFR2 agonism research in immunology journal

  StreetInsider · Nov 10, 8:10 AM EST

• Odyssey Therapeutics Announces Publication Highlighting Differentiated Therapeutic Potential of TNFR2 Agonism

  Yahoo Finance · Nov 10, 8:00 AM EST

• Among inflammation-controlling lung cells, one subgroup rose from 22% to 66% after one dose in mice.

  Stock Titan · Nov 10, 8:00 AM EST

• Odyssey Therapeutics, Inc. - Common Stock (Nasdaq:ODTX) Stock Quote

  FinancialContent · Nov 9, 4:00 PM EST

• Odyssey Therapeutics (Nasdaq:ODTX) - Stock Analysis

  Simply Wall St · Nov 8, 8:39 PM EST

• H.C. Wainwright Initiates Odyssey Therapeutics(ODTX.US) With Buy Rating, Announces Target Price $40

  Moomoo · Nov 6, 9:36 AM EST

• HC Wainwright & Co. assumes coverage of Odyssey Therapeutics at Buy, sets price target at $40

  TradingView · Nov 6, 7:10 AM EST

• Odyssey Therapeutics (NasdaqCM:ODTX) Stock Forecast & Analyst Predictions

  Simply Wall St · Nov 6, 3:00 AM EST

• FMR LLC and Abigail P. Johnson Reveal 13.0% Ownership Stake in Odyssey Therapeutics

  Kalkine Media · Nov 5, 1:34 PM EST

• A Fidelity pool has a 6% interest in Odyssey Therapeutics (ODTX), where FMR also reports ownership.

  Stock Titan · Nov 5, 1:23 PM EST

Odyssey Therapeutics, Inc. key financials

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 10-Q10-Q2026-11-04
• 8-K8-K2026-11-04
• 8-K8-K2026-10-20
• 8-K8-K2026-09-09
• 10-Q10-Q2026-08-06
• 8-K8-K2026-08-04
• 8-K8-K2026-06-23
• 10-Q10-Q2026-06-17
• 8-K8-K2026-06-17
• 8-K8-K2026-05-11
• S-1S-12026-04-17
• S-1S-12025-01-17

About Odyssey Therapeutics, Inc.

Ticker

ODTX (Nasdaq)

Industry

Biological Products, (No Diagnostic Substances)

Headquarters

Boston, MA

Incorporated in

DE

Fiscal year end

December 31

SEC CIK

1882782

Frequently asked questions